Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Neurosurg Psychiatry

Retrieve available abstracts of 54 articles:
HTML format
Text format



Single Articles


    April 2019
  1. BROWNLEE WJ, Solanky B, Prados F, Yiannakas M, et al
    Cortical grey matter sodium accumulation is associated with disability and secondary progressive disease course in relapse-onset multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Apr 4. pii: jnnp-2018-319634.
    PubMed     Text format     Abstract available


    March 2019
  2. RAGONESE P
    Food of the gods for the treatment of multiple sclerosis related fatigue?
    J Neurol Neurosurg Psychiatry. 2019 Mar 4. pii: jnnp-2018-319926.
    PubMed     Text format    


  3. COE S, Cossington J, Collett J, Soundy A, et al
    A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Mar 4. pii: jnnp-2018-319496.
    PubMed     Text format     Abstract available


  4. CRIELAARD L, Kavaliunas A, Ramanujam R, Olsson T, et al
    Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2019 Mar 1. pii: jnnp-2018-319913.
    PubMed     Text format     Abstract available


    February 2019
  5. ZHANG Y, Zhou Y, van der Mei IAF, Simpson S, et al
    Lipid-related genetic polymorphisms significantly modulate the association between lipids and disability progression in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Feb 19. pii: jnnp-2018-319870.
    PubMed     Text format     Abstract available


    January 2019
  6. MANJALY ZM, Harrison NA, Critchley HD, Do CT, et al
    Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 25. pii: jnnp-2018-320050.
    PubMed     Text format     Abstract available


  7. KALINCIK T, Kubala Havrdova E, Horakova D, Izquierdo G, et al
    Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 13. pii: jnnp-2018-319831.
    PubMed     Text format     Abstract available


  8. FAREZ MF
    Food allergies and multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 10. pii: jnnp-2018-319585.
    PubMed     Text format    


  9. ATKINS HL
    Another brick in the wall: further evidence supporting the role of haematopoietic stem cell transplantation in treating multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 10. pii: jnnp-2018-319715.
    PubMed     Text format    


    December 2018
  10. FAKIH R, Diaz-Cruz C, Chua AS, Gonzalez C, et al
    Food allergies are associated with increased disease activity in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Dec 18. pii: jnnp-2018-319301.
    PubMed     Text format     Abstract available


  11. MOORE JJ, Massey JC, Ford CD, Khoo ML, et al
    Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Dec 11. pii: jnnp-2018-319446.
    PubMed     Text format     Abstract available


    November 2018
  12. CHARALAMBOUS T, Tur C, Prados F, Kanber B, et al
    Structural network disruption markers explain disability in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Nov 22. pii: jnnp-2018-318440.
    PubMed     Text format     Abstract available


    October 2018
  13. OCHI H
    Novel prognostic predictor of brain atrophy in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Oct 15. pii: jnnp-2018-319376.
    PubMed     Text format    


    September 2018
  14. PALACE J, Duddy M, Lawton M, Bregenzer T, et al
    Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.
    J Neurol Neurosurg Psychiatry. 2018 Sep 21. pii: jnnp-2018-318360.
    PubMed     Text format     Abstract available


  15. KOUTSIS G, Breza M, Velonakis G, Tzartos J, et al
    X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association.
    J Neurol Neurosurg Psychiatry. 2018 Sep 8. pii: jnnp-2018-319014.
    PubMed     Text format     Abstract available


    July 2018
  16. JACOBS BM, Ammoscato F, Giovannoni G, Baker D, et al
    Cladribine: mechanisms and mysteries in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Jul 10. pii: jnnp-2017-317411.
    PubMed     Text format     Abstract available


  17. LANDI D, Ragonese P, Prosperini L, Nociti V, et al
    Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Jul 3. pii: jnnp-2018-318468.
    PubMed     Text format     Abstract available


    June 2018
  18. CHEN J, Taylor BV, Blizzard L, Simpson S Jr, et al
    Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    J Neurol Neurosurg Psychiatry. 2018 Jun 19. pii: jnnp-2018-318228.
    PubMed     Text format     Abstract available


    May 2018
  19. TAYLOR BV
    Search for a prognostic biomarker in multiple sclerosis: a step in the right direction?
    J Neurol Neurosurg Psychiatry. 2018 May 15. pii: jnnp-2018-318326.
    PubMed     Text format    


  20. RATHBONE E, Durant L, Kinsella J, Parker AR, et al
    Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 May 9. pii: jnnp-2018-317947.
    PubMed     Text format     Abstract available


    April 2018
  21. CERQUEIRA JJ, Compston DAS, Geraldes R, Rosa MM, et al
    Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
    J Neurol Neurosurg Psychiatry. 2018 Apr 4. pii: jnnp-2017-317509.
    PubMed     Text format    


    March 2018
  22. WIJNANDS JMA, Zhu F, Kingwell E, Fisk JD, et al
    Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
    J Neurol Neurosurg Psychiatry. 2018 Mar 30. pii: jnnp-2017-317493.
    PubMed     Text format     Abstract available


  23. POTTGEN J, Moss-Morris R, Wendebourg JM, Feddersen L, et al
    Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Mar 16. pii: jnnp-2017-317463.
    PubMed     Text format     Abstract available


    December 2017
  24. PATTI F
    Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Dec 23. pii: jnnp-2017-317380.
    PubMed     Text format    


  25. STURNER KH, Stellmann JP, Dorr J, Paul F, et al
    A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).
    J Neurol Neurosurg Psychiatry. 2017 Dec 16. pii: jnnp-2017-317101.
    PubMed     Text format     Abstract available


  26. COCOZZA S, Petracca M, Mormina E, Buyukturkoglu K, et al
    Cerebellar lobule atrophy and disability in progressive MS.
    J Neurol Neurosurg Psychiatry. 2017;88:1065-1072.
    PubMed     Text format     Abstract available


    October 2017
  27. AZARY S, Schreiner T, Graves J, Waldman A, et al
    Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Oct 9. pii: jnnp-2017-315936.
    PubMed     Text format     Abstract available


  28. FITZGERALD K
    Diet and disease modification in multiple sclerosis: a nutritional epidemiology perspective.
    J Neurol Neurosurg Psychiatry. 2017 Oct 9. pii: jnnp-2017-316375.
    PubMed     Text format    


  29. MEIJER KA, Eijlers AJC, Geurts JJG, Schoonheim MM, et al
    Staging of cortical and deep grey matter functional connectivity changes in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Oct 6. pii: jnnp-2017-316329.
    PubMed     Text format     Abstract available


    September 2017
  30. GAJOFATTO A, Nourbakhsh B, Benedetti MD, Waubant E, et al
    Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Sep 22. pii: jnnp-2017-316911.
    PubMed     Text format    


  31. PATERGNANI S, Castellazzi M, Bonora M, Marchi S, et al
    Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals.
    J Neurol Neurosurg Psychiatry. 2017 Sep 2. pii: jnnp-2017-316234.
    PubMed     Text format    


    August 2017
  32. SPENCER JI, Bell JS, DeLuca GC
    Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier.
    J Neurol Neurosurg Psychiatry. 2017 Aug 31. pii: jnnp-2017-316011.
    PubMed     Text format     Abstract available


  33. CALABRESE M, Pitteri M, Farina G, Bajrami A, et al
    Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
    J Neurol Neurosurg Psychiatry. 2017 Aug 26. pii: jnnp-2017-316236.
    PubMed     Text format     Abstract available


  34. CLAFLIN SB, van der Mei IAF, Taylor BV
    Complementary and alternative treatments of multiple sclerosis: a review of the evidence from 2001 to 2016.
    J Neurol Neurosurg Psychiatry. 2017 Aug 2. pii: jnnp-2016-314490.
    PubMed     Text format     Abstract available


  35. KOCH-HENRIKSEN N, Laursen B, Stenager E, Magyari M, et al
    Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.
    J Neurol Neurosurg Psychiatry. 2017;88:626-631.
    PubMed     Text format     Abstract available


  36. GRYTTEN N
    Survival in multiple sclerosis: things have changed.
    J Neurol Neurosurg Psychiatry. 2017;88:618.
    PubMed     Text format    


  37. LASCANO AM, Lalive PH, Hardmeier M, Fuhr P, et al
    Clinical evoked potentials in neurology: a review of techniques and indications.
    J Neurol Neurosurg Psychiatry. 2017;88:688-696.
    PubMed     Text format     Abstract available


    July 2017
  38. ZHOU Y, Graves JS, Simpson S Jr, Charlesworth JC, et al
    Genetic variation in the gene LRP2 increases relapse risk in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Jul 24. pii: jnnp-2017-315971.
    PubMed     Text format     Abstract available


  39. PREZIOSA P, Rocca MA, Mesaros S, Meani A, et al
    Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria.
    J Neurol Neurosurg Psychiatry. 2017 Jul 19. pii: jnnp-2017-315863.
    PubMed     Text format    


  40. EISELE P, Szabo K, Alonso A, Ong M, et al
    Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Jul 14. pii: jnnp-2017-316102.
    PubMed     Text format    


    May 2017
  41. TETTEY P, Simpson S, Taylor B, Ponsonby AL, et al
    An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event.
    J Neurol Neurosurg Psychiatry. 2017;88:395-401.
    PubMed     Text format     Abstract available


    April 2017
  42. RAGONESE P
    Mortality studies for multiple sclerosis: still a useful tool to analyse long-term outcome.
    J Neurol Neurosurg Psychiatry. 2017 Apr 28. pii: jnnp-2017-315591.
    PubMed     Text format    


  43. OKADA K, Kobata M, Sennari Y, Iwanaka Y, et al
    Levels of nitric oxide metabolites in cerebrospinal fluid correlate with cognitive impairment in early stage multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Apr 26. pii: jnnp-2017-315585.
    PubMed     Text format    


  44. LUNDE HB, Assmus J, Kjell-Morten M, Bo L, et al
    Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.
    J Neurol Neurosurg Psychiatry. 2017 Apr 1. pii: jnnp-2016-315238.
    PubMed     Text format     Abstract available


  45. COMI G, De Stefano N, Freedman MS, Barkhof F, et al
    Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
    J Neurol Neurosurg Psychiatry. 2017;88:285-294.
    PubMed     Text format     Abstract available


    March 2017
  46. MURPHY R, O'Donoghue S, Counihan T, McDonald C, et al
    Neuropsychiatric syndromes of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Mar 11. pii: jnnp-2016-315367.
    PubMed     Text format     Abstract available


  47. ZALEWSKI NL, Morris PP, Weinshenker BG, Lucchinetti CF, et al
    Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders.
    J Neurol Neurosurg Psychiatry. 2017;88:218-225.
    PubMed     Text format     Abstract available


    February 2017
  48. JURYNCZYK M, Tackley G, Kong Y, Geraldes R, et al
    Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
    J Neurol Neurosurg Psychiatry. 2017;88:132-136.
    PubMed     Text format     Abstract available


    December 2016
  49. ROCCA MA, Filippi M
    Modulation of cortical excitability to normalise brain function and improve cognition in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Dec 30. pii: jnnp-2016-315195.
    PubMed     Text format    


  50. HULST HE, Goldschmidt T, Nitsche MA, de Wit SJ, et al
    rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Dec 14. pii: jnnp-2016-314224.
    PubMed     Text format     Abstract available


    November 2016
  51. TAO C, Simpson S Jr, van der Mei I, Blizzard L, et al
    Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Nov 3. pii: jnnp-2016-314013.
    PubMed     Text format     Abstract available


    October 2016
  52. MOROSO A, Ruet A, Lamargue-Hamel D, Munsch F, et al
    Posterior lobules of the cerebellum and information processing speed at various stages of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Oct 27. pii: jnnp-2016-313867.
    PubMed     Text format     Abstract available


    September 2016
  53. LIZAK N, Lugaresi A, Alroughani R, Lechner-Scott J, et al
    Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Sep 28. pii: jnnp-2016-313976.
    PubMed     Text format     Abstract available


  54. KAWACHI I, Lassmann H
    Neurodegeneration in multiple sclerosis and neuromyelitis optica.
    J Neurol Neurosurg Psychiatry. 2016 Sep 26. pii: jnnp-2016-313300.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: